Apmonia Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $11.7M

  • Investors
  • 11

Apmonia Therapeutics General Information

Description

Developer of peptide-based biotechnology designed to provide therapeutic strategies for multiple types of cancer. The company focuses on creating drugs to treat glioblastoma, ovarian, colorectal, and pancreatic cancer, targeting the tumor microenvironment, and offers new therapeutic perspectives, particularly for the treatment of solid tumors, enabling patients to help fight cancer and helping researchers to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide.

Contact Information

Website
www.apmonia-therapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2 rue Léon Patoux
  • 51100 Reims
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2 rue Léon Patoux
  • 51100 Reims
  • France

Apmonia Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apmonia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 03-Feb-2026 $11.7M Completed Clinical Trials - Phase 1
9. Equity Crowdfunding 29-Oct-2025 Completed Clinical Trials - Phase 1
8. Later Stage VC Cancelled Clinical Trials - Phase 1
7. Grant 16-Jul-2024 Completed Clinical Trials - Phase 1
6. Grant 23-Apr-2024 Completed Clinical Trials - Phase 1
5. Early Stage VC 06-Sep-2022 Completed Clinical Trials - Phase 1
4. Early Stage VC 10-Feb-2022 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator Completed Clinical Trials - Phase 1
2. Angel (individual) 01-Sep-2020 $189K $189K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Apmonia Therapeutics’s complete valuation and funding history, request access »

Apmonia Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Apmonia Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Apmonia Therapeutics Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

Apmonia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026027599-A1 Inhibitory peptides for cathepsin d and lrp-1 interaction Pending 30-Jul-2024
AU-2024374249-A1 Formulations of peptides inhibiting the tsp-cd47 interaction Pending 03-Nov-2023
EP-4801465-A1 Formulations of peptides inhibiting the tsp-cd47 interaction Pending 03-Nov-2023
WO-2025093688-A1 Formulations of peptides inhibiting the tsp-cd47 interaction Inactive 03-Nov-2023 A61K47/44

Apmonia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apmonia Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Capital Cell PE-Backed Company Minority
Key Ventures Venture Capital Minority
European Innovation Council Accelerator/Incubator Minority
Bpifrance Sovereign Wealth Fund Minority
Angels Santé Angel Group Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Apmonia Therapeutics FAQs

  • When was Apmonia Therapeutics founded?

    Apmonia Therapeutics was founded in 2019.

  • Where is Apmonia Therapeutics headquartered?

    Apmonia Therapeutics is headquartered in Reims, France.

  • What is the size of Apmonia Therapeutics?

    Apmonia Therapeutics has 15 total employees.

  • What industry is Apmonia Therapeutics in?

    Apmonia Therapeutics’s primary industry is Drug Discovery.

  • Is Apmonia Therapeutics a private or public company?

    Apmonia Therapeutics is a Private company.

  • What is the current valuation of Apmonia Therapeutics?

    The current valuation of Apmonia Therapeutics is .

  • What is Apmonia Therapeutics’s current revenue?

    The current revenue for Apmonia Therapeutics is .

  • How much funding has Apmonia Therapeutics raised over time?

    Apmonia Therapeutics has raised $23.9M.

  • Who are Apmonia Therapeutics’s investors?

    Capital Cell, Key Ventures, European Innovation Council, Bpifrance, and Angels Santé are 5 of 11 investors who have invested in Apmonia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process